🇺🇸 FDA
Pipeline program

RO7247669

BP43963

Phase 2 small_molecule completed

Quick answer

RO7247669 for Melanoma is a Phase 2 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

Program details

Company
Hoffmann-La Roche
Indication
Melanoma
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials